Gold Nanoparticle-Incorporated Chitosan Nanogels as a Theranostic Nanoplatform for CT Imaging and Tumour Chemotherapy
Zhe Liu,Dong Zhou,Xuan Yan,Lan Xiao,Pei Wang,Junchao Wei,Lan Liao
DOI: https://doi.org/10.2147/ijn.s375999
IF: 7.033
2022-10-12
International Journal of Nanomedicine
Abstract:Zhe Liu, 1– 3, &ast Dong Zhou, 4, &ast Xuan Yan, 1 Lan Xiao, 5, 6 Pei Wang, 1– 3 Junchao Wei, 1– 4 Lan Liao 1– 3 1 The Affiliated Stomatological Hospital of Nanchang University, Nanchang, People's Republic of China; 2 The Key Laboratory of Oral Biomedicine, Nanchang, People's Republic of China; 3 Jiangxi Province Clinical Research Center for Oral Diseases, Nanchang, People's Republic of China; 4 School of Chemistry and Chemical Engineering, Nanchang University, Nanchang, People's Republic of China; 5 School of Mechanical, Medical & Process Engineering, Centre for Biomedical Technologies, Queensland University of Technology (QUT), Brisbane, Australia; 6 Australia China Centre for Tissue Engineering and Regenerative Medicine, Kelvin Grove, Brisbane, Australia &astThese authors contributed equally to this work Correspondence: Junchao Wei; Lan Liao, Email ; Purpose: The translation of nanocarrier-based theranostics into cancer treatment is limited by their poor cellular uptake, low drug-loading capacity, uncontrolled drug release, and insufficient imaging ability. Methods: In this study, novel hybrid nanogels were fabricated as theranostic nanocarriers by modifying chitosan (CTS)/tripolyphosphate (TPP) nanoparticles (NPs) with polyacrylic acid (PAA) and further conjugating cysteine-functionalized gold nanoparticles (AuNPs). Results: The resultant nanogels, referred to as CTS/TPP/ (CTPA), exhibited excellent colloidal stability and a high encapsulation rate of 87% for the cationic drug doxorubicin (DOX). In the tumour microenvironment, the acidic pH and overexpression of lysozyme triggered to degrade and emit smaller nanoblocks (30– 40 nm), which sequentially released the drug in a tumour-responsive manner. Cellular uptake experiments demonstrated that CTPA facilitates the entry of DOX into the cytoplasm. Furthermore, as visualised through AuNP-mediated computed tomography (CT) imaging, enabled favourable accumulation in the tumour. Our in vitro and in vivo data demonstrated that CTPA enabled advanced tumour cell-targeting delivery of DOX, which showed greater anti-tumour activity and biosafety than free DOX. Conclusion: The natural polymer CTS was developed for degradable nanogels, which can precisely track drugs with high antitumour activity. Additionally, the surface adjustment strategy can be assembled to achieve cationic drug loading and high drug-loading capacity, controlled drug release, and sufficient imaging ability. Therefore, multifunctional CTPA enables efficient drug delivery and CT imaging, which is expected to provide a valuable strategy for designing advanced theranostic systems. Keywords: theranostic nanomaterial, degradability, computed tomography imaging, hybrid nanogel Theranostic nanocarriers have attracted increasing attention for cancer treatment. 1,2 As multifunctional devices, theranostic nanocarriers can be effectively combined with tumour markers to detect various diseases at low concentrations with high sensitivity. 3 Additionally, theranostic nanocarriers can reduce drug toxicity and meet low-dosage drug requirements. 4 Theranostic nanocarriers deliver drugs to the action site passively and/or actively, and also concurrently provide valuable diagnostic information, such as tumour location, drug distribution, and tumour response to treatment. 5,6 Currently, there are several types of theranostic nanocarriers, including magnetic nanoparticles (NPs), carbon quantum dots, and gold nanoparticles (AuNPs). Magnetic NPs can control the accumulation of drugs in specific parts of the tumour and reduce the general distribution of drugs, whereas carbon quantum dots can be prepared as electrochemical sensors by utilising their large surface area. AuNPs can be used as electrochemical sensors owing to their strong surface properties and easy modification. 7,8 Ideally, theranostic nanocarriers should enable a combined effective drug delivery and imaging diagnosis, which is a significant challenge for nanotechnology. 9 To achieve effective tumour-targeted drug delivery, carriers should enable stability in long-term circulation, proper drug distribution, deep tumour penetration, controlled drug release, and enhanced cellular uptake. 10,11 Generally, these functions largely depend on the properties of the particles, including size, charge, degradability, elasticity, and surface chemistry, which need to be elegantly tailored. 12,13 Furthermore, theranostic nanocarriers should enable the efficient conjugation of therapeutics and diagnostics, thereby satisf -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology